These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23553848)

  • 21. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.
    Lee RJ; Smith MR
    Cancer J; 2013; 19(1):90-8. PubMed ID: 23337762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
    Antonarakis ES; Heath EI; Posadas EM; Yu EY; Harrison MR; Bruce JY; Cho SY; Wilding GE; Fetterly GJ; Hangauer DG; Kwan MF; Dyster LM; Carducci MA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):883-92. PubMed ID: 23314737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases.
    Xu J; Higgins MJ; Tolaney SM; Come SE; Smith MR; Fornier M; Mahmood U; Baselga J; Yeap BY; Chabner BA; Isakoff SJ
    Oncologist; 2020 Aug; 25(8):652-660. PubMed ID: 32463152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma.
    Lacy S; Nielsen J; Yang B; Miles D; Nguyen L; Hutmacher M
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1061-1070. PubMed ID: 29667066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.
    Castellano D; Pablo Maroto J; Benzaghou F; Taguieva N; Nguyen L; Clary DO; Jonasch E
    Cancer Treat Rev; 2020 Sep; 89():102062. PubMed ID: 32659623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.
    Leone JP; Duda DG; Hu J; Barry WT; Trippa L; Gerstner ER; Jain RK; Tan S; Lawler E; Winer EP; Lin NU; Tolaney SM
    Breast Cancer Res Treat; 2020 Jan; 179(1):113-123. PubMed ID: 31541381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor.
    Markowitz JN; Fancher KM
    Pharmacotherapy; 2018 Mar; 38(3):357-369. PubMed ID: 29283440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.
    Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE
    Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
    Twardowski PW; Beumer JH; Chen CS; Kraft AS; Chatta GS; Mitsuhashi M; Ye W; Christner SM; Lilly MB
    Anticancer Drugs; 2013 Aug; 24(7):743-53. PubMed ID: 23652277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
    Basch E; Autio KA; Smith MR; Bennett AV; Weitzman AL; Scheffold C; Sweeney C; Rathkopf DE; Smith DC; George DJ; Higano CS; Harzstark AL; Sartor AO; Gordon MS; Vogelzang NJ; de Bono JS; Haas NB; Corn PG; Schimmoller F; Scher HI
    Eur Urol; 2015 Feb; 67(2):310-8. PubMed ID: 24631409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
    Zuo RC; Apolo AB; DiGiovanna JJ; Parnes HL; Keen CM; Nanda S; Dahut WL; Cowen EW
    JAMA Dermatol; 2015 Feb; 151(2):170-7. PubMed ID: 25427282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
    Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
    Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.
    Ryan CJ; Shah S; Efstathiou E; Smith MR; Taplin ME; Bubley GJ; Logothetis CJ; Kheoh T; Kilian C; Haqq CM; Molina A; Small EJ
    Clin Cancer Res; 2011 Jul; 17(14):4854-61. PubMed ID: 21632851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
    Aragon-Ching JB; Jain L; Gulley JL; Arlen PM; Wright JJ; Steinberg SM; Draper D; Venitz J; Jones E; Chen CC; Figg WD; Dahut WL
    BJU Int; 2009 Jun; 103(12):1636-40. PubMed ID: 19154507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
    Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
    Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E
    PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
    Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM
    J Transl Med; 2016 Jan; 14():12. PubMed ID: 26762579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
    Agarwal N; McGregor B; Maughan BL; Dorff TB; Kelly W; Fang B; McKay RR; Singh P; Pagliaro L; Dreicer R; Srinivas S; Loriot Y; Vaishampayan U; Goel S; Curran D; Panneerselvam A; Schwickart M; Choueiri TK; Pal S
    Lancet Oncol; 2022 Jul; 23(7):899-909. PubMed ID: 35690072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.